Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 1
2010 2
2011 4
2012 6
2013 7
2014 11
2015 8
2016 16
2017 17
2018 10
2019 9
2020 23
2021 20
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Results by year
Filters applied: . Clear all
Page 1
Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC. Gross AM, et al. Among authors: peer cj. N Engl J Med. 2020 Apr 9;382(15):1430-1442. doi: 10.1056/NEJMoa1912735. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187457 Free PMC article. Clinical Trial.
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Szmulewitz RZ, et al. Among authors: peer cj. J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590007 Free PMC article. Clinical Trial.
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA. Conlon KC, et al. Among authors: peer cj. J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17. J Clin Oncol. 2015. PMID: 25403209 Free PMC article. Clinical Trial.
Pharmacogenomics and histone deacetylase inhibitors.
Goey AK, Sissung TM, Peer CJ, Figg WD. Goey AK, et al. Among authors: peer cj. Pharmacogenomics. 2016 Nov;17(16):1807-1815. doi: 10.2217/pgs-2016-0113. Epub 2016 Oct 21. Pharmacogenomics. 2016. PMID: 27767376 Free PMC article. Review.
Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.
Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y. Marzi L, et al. Among authors: peer cj. Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10. Mol Cancer Ther. 2018. PMID: 29748210 Free PMC article.
Subcutaneous Atezolizumab: A Jab Without a Benefit.
Peer CJ, Zimmerman SM, Figg WD, Goldstein DA, Ratain MJ. Peer CJ, et al. Clin Pharmacol Drug Dev. 2022 Jan;11(1):134-135. doi: 10.1002/cpdd.1061. Epub 2021 Dec 23. Clin Pharmacol Drug Dev. 2022. PMID: 34951144 No abstract available.
Ibrutinib's off-target mechanism: cause for dose optimization.
Zimmerman SM, Peer CJ, Figg WD. Zimmerman SM, et al. Among authors: peer cj. Cancer Biol Ther. 2021 Dec 2;22(10-12):529-531. doi: 10.1080/15384047.2021.1980313. Epub 2021 Oct 10. Cancer Biol Ther. 2021. PMID: 34632931
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Madan RA, et al. Among authors: peer cj. BJU Int. 2021 Apr;127(4):435-444. doi: 10.1111/bju.15227. Epub 2020 Oct 23. BJU Int. 2021. PMID: 32969563 Clinical Trial.
121 results